Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Saturday, June 29, 2019

Application of High-Sensitivity Troponin in Suspected Myocardial Infarction
Chest pain suggestive of myocardial infarction is a leading cause of presentation to the emergency department worldwide. In addition to the electrocardiogram and clinical symptoms, the serial measurement of cardiac troponin is key in ruling out or diagnosing myocardial infarction. With the…
NEJM : Research
6h
Early Sedation with Dexmedetomidine in Critically Ill Patients
Sedation is a component of the care of critically ill patients who are undergoing mechanical ventilation, but the appropriate choice of a primary sedative agent remains uncertain. Propofol and midazolam, which act mainly through pathways mediated by γ-aminobutyric acid, are widely used for this…
NEJM : Research
6h
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Systemic sclerosis is a rare and heterogeneous autoimmune disease characterized by immune dysregulation, microvascular damage, and organ fibrosis. Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis that tends to occur early in the course of disease; the condition places…
NEJM : Research
6h
Detection of Brain Activation in Unresponsive Patients with Acute Brain Injury
Clinically unresponsive patients can have electroencephalographic (EEG) or magnetic resonance imaging (MRI) evidence of brain activation in response to spoken commands. A meta-analysis has reported that 14% of chronically unresponsive patients may have a dissociation between behavior and brain…
NEJM : Research
6h
Procedural Volume and Outcomes for Transcatheter Aortic-Valve Replacement
Transcatheter aortic-valve replacement (TAVR) was approved in 2011 in the United States. As a condition of reimbursement, the Centers for Medicare and Medicaid Services (CMS) requires TAVR programs to perform a minimum of 20 TAVR procedures per year or 40 over a period of 2 years. Although other…
NEJM : Research
6h
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Clinicopathological features, including tumor size, histologic grade, and the presence of axillary lymph-node metastases, provide prognostic information about disease recurrence in women who have localized breast cancer after surgery, but these features have not been shown to be predictive of…
NEJM : Research
6h
Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease
Management of the care of patients with stable coronary artery disease is based on reduction of risk factors, guideline-directed medical therapy, and revascularization in those with persistent symptoms or proven ischemia. In symptomatic patients with risk factors for coronary artery disease, two…
NEJM : Research
6h
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Multiple sclerosis is a progressive demyelinating, inflammatory, and neurodegenerative autoimmune disease that results in the formation of lesions in the protective layer around nerves in the brain and spinal cord. Goals in the treatment of patients’ disabling symptoms include reducing the…
NEJM : Research
6h
Medicaid Work Requirements — Results from the First Year in Arkansas
In recent years, policymakers have introduced unprecedented changes to Medicaid. As of April 2019, nine states have received approval by means of a federal waiver to implement work requirements in Medicaid, and six have applications pending. According to the Centers for Medicare and Medicaid…
NEJM : Research
6h
C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia
Achondroplasia is the most common form of disproportionate short stature, with a prevalence of 1 in 25,000 live births. The condition is caused by an autosomal dominant mutation in the fibroblast growth factor receptor 3 gene (FGFR3) that constitutively activates the mitogen-activated protein…
NEJM : Research
6h
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Sickle cell disease affects approximately 100,000 persons in the United States and reduces life expectancy by approximately 30 years. The disease is caused by a single amino acid substitution resulting in the production of sickle hemoglobin (HbS). HbS polymerizes when deoxygenated, resulting in…
NEJM : Research
6h
Targeting Huntingtin Expression in Patients with Huntington’s Disease
Huntington’s disease is a progressive neurodegenerative disorder inherited as an autosomal-dominant trait, with onset typically occurring in mid-adult life and characterized by movement disorder, cognitive decline, and behavioral symptoms. Huntington’s disease is caused by CAG trinucleotide repeat…
NEJM : Research
6h
Clinical Metagenomic Sequencing for Diagnosis of Meningitis and Encephalitis
The existing paradigm for diagnosing infections relies on the physician formulating a differential diagnosis on the basis of a patient’s history, clinical presentation, and imaging findings, followed by serial laboratory testing. This traditional approach is particularly challenging for…
NEJM : Research
6h
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
The increasing prevalence of type 2 diabetes during recent decades is the primary factor accounting for the substantial global increase in end-stage kidney disease. Currently, more than 3 million people worldwide are estimated to be receiving treatment for kidney failure, with predictions that the…
NEJM : Research
6h
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
Women with locally advanced (International Federation of Gynecology and Obstetrics [FIGO] stage III or IVA) endometrial carcinoma are a heterogeneous group of patients who are at risk for both local and systemic disease recurrence. Clinical and pathologic factors affecting the risk of recurrence…
NEJM : Research
6h
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Cardiovascular disease is the primary cause of death in patients with type 2 diabetes, and the ruling out of an excess cardiovascular risk is a regulatory requirement for new glucose-lowering therapies. Glucagon-like peptide-1 (GLP-1) receptor agonists are well-established glucose-lowering…
NEJM : Research
6h
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Type 1 diabetes is caused by the autoimmune destruction of insulin-producing beta cells in the islets of Langerhans, which leads to dependence on exogenous insulin for survival. Approximately 1 million to 1.5 million Americans have type 1 diabetes, which is one of the most common diseases of…
NEJM : Research
6h
Vitamin D Supplementation and Prevention of Type 2 Diabetes
More than 84 million adults in the United States have an increased risk of type 2 diabetes, based on a fasting glucose or glycated hemoglobin level above the normal range but below the threshold for diabetes. Persons at high risk for type 2 diabetes who are overweight or obese and who have elevated…
NEJM : Research
6h
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up
Observational cohort studies have shown increasing risks of both macrovascular and microvascular events with increasing average blood glucose levels. Trials involving patients with type 1 diabetes and patients with new-onset type 2 diabetes showed that improving glucose control reduced the…
NEJM : Research

No comments:

Post a Comment